

This is a repository copy of *Using the Human Factors Framework to understand the origins of medication safety problems in community pharmacy : A qualitative study*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/185971/>

Version: Accepted Version

Article:

Al Juffali, Lobna, Al-Aqeel, Sinaa, Knapp, Peter orcid.org/0000-0001-5904-8699 et al. (3 more authors) (2019) Using the Human Factors Framework to understand the origins of medication safety problems in community pharmacy : A qualitative study. Research in social & administrative pharmacy : RSAP. pp. 558-567. ISSN 1934-8150

<https://doi.org/10.1016/j.sapharm.2018.07.010>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Manuscript Details

Manuscript number	RSAP_2018_90
Title	Using the Human Factors Framework to understand the origins of medication safety problems in community pharmacy in Saudi Arabia: A qualitative study
Article type	Research Paper

Abstract

ABSTRACT Background: Community pharmacy practice in the Kingdom of Saudi Arabia (KSA) faces many challenges. In KSA, there is a lack of empirical research about medication safety in this setting. Objective: To explore the safety problems associated with medication supply from community pharmacies in KSA and compare different stakeholder perspectives. Methods: Four focus groups and individual interviews were conducted in Riyadh, KSA, in February-May 2013. All group discussions were recorded, transcribed and translated from Arabic into English, except the professional group, which was conducted in English. Thematic analysis was performed using the Human Factors Framework (HFF). Results: The groups comprised “professionals” (n=8; one female), community pharmacists (n=4; all male) and two pharmacy user groups (females, n=11 and males, n=8). Medication safety problems identified were categorised into nine categories representing the HFF. Seven main themes were identified from these categories: commercial pressure on community pharmacy; illegal supply of prescription medication; lack of enforcement of regulations; the healthcare system; self-medication; patient trust in pharmacists; and communication failure. Themes that emerged only from the “professionals” and community pharmacists were the different role of the regulatory organisations and the reasons behind lack of enforcement, while the community pharmacist group focused on the relationship between owners and managers. Pharmacy users expressed a need for information about medication and that the primary role of the pharmacist should be as an information provider. Furthermore, they perceived pharmacists to be vendors rather than healthcare professionals. Conclusion: Many medication safety problems were identified, attributable to individuals (patient, pharmacist), pharmacy and organisational factors. These results will be used to develop interventions to improve medication safety.

Keywords	Patient safety;Community pharmacy; Human factors;Medication errors; Drug related side effects ;adverse reactions.
Manuscript category	Research Paper
Corresponding Author	Lobna Al Juffali
Corresponding Author's Institution	king saud university
Order of Authors	Lobna Al Juffali, SA Al-Aqeel, Peter Knapp, Kathryn Mearns, Hannah Family, Margaret (Mags) Watson
Suggested reviewers	Darren Ashcroft

Submission Files Included in this PDF

File Name [File Type]

Cover letter RSAP.doc [Cover Letter]

Tilte page.docx [Title Page (with Author Details)]

ANON, manuscript 2822018.docx [Manuscript (without Author Details)]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

**To,
The Editors,**

Research in Social and Administrative Pharmacy

Subject: Submission of an Original Article, “Using the Human Factors Framework to understand the origins of medication safety problems in community pharmacy in Saudi Arabia: A qualitative study”

Dear Sir/Ma’am

We are submitting an Original Article, “Using the Human Factors Framework to understand the origins of medication safety problems in community pharmacy in Saudi Arabia: A qualitative study” for consideration for publication in Research in Social and Administrative Pharmacy.

Most medication safety studies are undertaken in secondary care, but the main burden of care is in primary care. However, less is known about medication safety outside hospital environments. Research undertaken in community pharmacy settings has mostly focused on detecting and measuring rates of medication errors and near misses. Community pharmacy in Saudi Arabia faces many challenges. There is a lack of empirical research about medication safety in this setting in Saudi Arabia and research is needed. Qualitative studies are limited in this setting in Saudi Arabia. This study aimed to identify and explore the main safety problems associated with medication supply from community pharmacies in Saudi Arabia.

This article provided insights about the medication safety problems that occur to patients using medication from the community pharmacy from different perspectives: Policy makers, pharmacy owners, community pharmacist and pharmacy users. Human factors framework allowed a system approach in analysing the problems and safety in community pharmacy. Highlighting these problems provides evidence to policy makers, healthcare providers about the potential harm to patients and allow future interventions and research to focus on the quality and safety of community pharmacy and primary care generally.

I, Lobna Al Juffali (Corresponding author) certify that the manuscript is being submitted by me (Corresponding author) on behalf of all the authors.

This research has been reviewed and approved by the College Ethics Review Board, University of Aberdeen, UK.

Thank you

Sincerely,

Lobna Al Juffali

Author Details:

Lobna Al Juffali, Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Sinaa Al-aqeel , Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

Peter Knapp, Department of Health Sciences and the Hull York Medical School, University of York, UK

Kathryn Mearns, Principal Human Factors Consultant, Wood Group, Aberdeen, UK.

Hannah Family, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

Margaret Watson, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

Corresponding author Lobna Al Juffali

Email: laljaffali@ksu.edu.sa

Address: [King Saud University P O Box 22452, Riyadh, Kingdom of Saudi Arabia 11496](#)

Telephone number: [+966505172290](tel:+966505172290)

[

1
2
3
4
5 **Using the Human Factors Framework to understand the origins of**
6 **medication safety problems in community pharmacy in Saudi Arabia: A**
7 **qualitative study**
8
9

10 Lobna Al Juffali ^a, Sinaa Al-aqeel ^a, Peter Knapp ^b, Kathryn Mearns ^c, Hannah Family ^d, Margaret
11
12 Watson ^d
13

14
15 ^a Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia

16 ^b Department of Health Sciences and the Hull York Medical School, University of York, UK

17 ^c Principal Human Factors Consultant, Wood Group, Aberdeen, UK

18 ^d Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
19
20
21
22

23 **Corresponding author Lobna Al Juffali**
24

25 **Email:** laljaffali@ksu.edu.sa
26

27 **Address:** [King Saud University P O Box 22452, Riyadh, Kingdom of Saudi Arabia 11496](#)
28

29 **Telephone number:** [+966505172290](tel:+966505172290)
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **1 ABSTRACT**
6

7 **2 Background:** Community pharmacy practice in the Kingdom of Saudi Arabia (KSA) faces many
8 challenges. In KSA, there is a lack of empirical research about medication safety in this setting.
9

10 **4 Objective:** To explore the safety problems associated with medication supply from community
11 pharmacies in KSA and compare different stakeholder perspectives.
12
13

14 **6 Methods:** Four focus groups and individual interviews were conducted in Riyadh, KSA, in
15 February-May 2013. All group discussions were recorded, transcribed and translated from
16 Arabic into English, except the professional group, which was conducted in English. Thematic
17 analysis was performed using the Human Factors Framework (HFF).
18
19
20

21 **10 Results:** The groups comprised “professionals” (n=8; one female), community pharmacists (n=4;
22 all male) and two pharmacy user groups (females, n=11 and males, n=8). Medication safety
23 problems identified were categorised into nine categories representing the HFF. Seven main
24 themes were identified from these categories: commercial pressure on community pharmacy;
25 illegal supply of prescription medication; lack of enforcement of regulations; the healthcare
26 system; self-medication; patient trust in pharmacists; and communication failure. Themes that
27 emerged only from the “professionals” and community pharmacists were the different role of
28 the regulatory organisations and the reasons behind lack of enforcement, while the community
29 pharmacist group focused on the relationship between owners and managers. Pharmacy users
30 expressed a need for information about medication and that the primary role of the pharmacist
31 should be as an information provider. Furthermore, they perceived pharmacists to be vendors
32 rather than healthcare professionals.
33
34
35
36
37
38
39

40 **22 Conclusion:** Many medication safety problems were identified, attributable to individuals
41 (patient, pharmacist), pharmacy and organisational factors. These results will be used to
42 develop interventions to improve medication safety.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

60
61
62
63 **26 BACKGROUND**
64

65 27 The World Health Organisation has highlighted safety in primary care as an international
66 28 challenge.[1] In primary healthcare, adverse drug events (ADEs) are reported to occur in 25% of
67 29 outpatients, almost half of which (11%) are preventable.[2] Research undertaken in the
70 30 community pharmacy setting has mostly focused on detecting and measuring medication errors
71 31 and near misses.[3]

72
73 32 Studies in the Kingdom of Saudi Arabia (KSA) have shown high levels of hospital admissions
74 33 associated with drug-related problems (DRPs), of which the most common causes were ADEs, a
75 34 failure to receive medication and medication non-compliance.[4,5] A range of challenges to
76 35 medication safety in KSA were identified: limited use of technology; illegal supply of
77 36 prescription only medication (POM); communication gaps between healthcare institutions;
78 37 under-reporting of ADEs and communication barriers.[6] Studies in KSA have mainly
79 38 investigated the problems either from a pharmacist or a pharmacy user perspective using
80 39 mostly surveys.[7-11] No qualitative studies have been conducted with pharmacy users or
81 40 other stakeholders, such as policy makers and pharmacy owners.

82
83
84
85
86
87
88 41 The application of theory may help to understand patient safety problems and a number of
89 42 relevant frameworks exist. [12-17] The Human Factors Framework (HFF) has potential to
90 43 enhance clinical performance by understanding the effects of factors such as teamwork, tasks,
91 44 equipment, workspace, culture and organisation on human behaviour and abilities, and
92 45 applying insights to clinical settings. [14-18] The HFF aids understanding of people's
93 46 capabilities and limitations, allowing design of better systems. It is a recognised tool to reduce
94 47 medication error rates or mitigate adverse medication effects. [12]

95
96
97
98
99 48 The purpose of our study was to explore and compare different stakeholder perspectives
100 49 regarding the safety problems associated with medication supply from community pharmacies
101 50 in KSA using the HFF. The stakeholders for whom medication safety is important include service
102 51 users, community pharmacists, pharmacy owners, as well as representatives from legal and
103 52 regulatory authorities.

104
105
106
107
108 **53 METHODS**
109

110 54 This qualitative study comprised a series of focus groups and interviews. Focus groups were
111 55 conducted with different stakeholders: healthcare professionals; community pharmacists; and
112 56 pharmacy users. Individual interviews were conducted with community pharmacists only.
113
114
115
116
117
118

119
120
121 **57 Sampling and recruitment**
122

123 **58** The study was conducted in Riyadh, the capital of KSA. The healthcare professional group (PG)
124 **59** was recruited purposively, identified through professional and personal networks.
125
126 **60**

127 **61** The community pharmacist group (CPG) was recruited using purposive, convenience and
128 **62** snowballing methods. Personal visits to pharmacies and telephone calls were made to invite
129 **63** participants. Telephone interviews were offered only to community pharmacists who could not
130 **64** attend the focus group due to job commitments.
131
132 **65**

133 **66** Pharmacy users aged 18 and older were eligible to participate. Different recruitment strategies
134 **67** were adopted to reflect the cultural constraints in Saudi society. For the female pharmacy user
135 **68** group (FPG), community centres and sites for social activities were sought in Riyadh. A non-
136 **69** profit childcare association providing free weekly parenting courses in community centres was
137 **70** identified, to recruit female attendees who were of various ages and educational backgrounds.
138 **71** For the male pharmacy user group (MPG), an announcement about a support group for
139 **72** caregivers of Alzheimer patients was sent via Twitter from the Alzheimer Society account. This
140 **73** support group is held once a month in a private training centre. The researcher (LJ) visited one
141 **74** of these support group meetings for recruitment purposes.
142
143 **75**

144 **76** All potential participants, irrespective of group, received an invitation letter and study
145 **77** information sheet. A consent form was provided by e-mail or personally, one week prior to the
146 **78** focus group. Each participant signed an individual informed consent statement prior to the
147 **79** commencement of the focus groups.
148
149

150 **80 Data collection**
151
152

153 **81** The focus groups were conducted using semi-structured topic guides (Supplementary Material)
154 **82** (one for FPG and MPG and one for the PG and CPG), which were informed by the literature and
155 **83** the HFF. Data were collected on participants' age, gender, and education background and
156 **84** practice experience. The PG was moderated by MW. The remaining focus groups were
157 **85** moderated by LJ, with SA in attendance. Before undertaking the group discussions, a pilot focus
158 **86** group was conducted with first year undergraduate pharmacy students to test questions and
159 **87** data collection methods.
160
161

162 **88 Research ethics**
163
164

165 **89** This study was completed as part of the first author's PhD thesis who undertook specific
166 **90** training regarding conducting and analysing qualitative research. Approval for this study was
167 **91** received from The College Ethics Review Board, University of Aberdeen, UK.
168
169
170
171
172
173
174
175
176
177

178
179
180 **92 Data management and analysis**
181

182 93 Each focus group was audio-recorded and transcribed verbatim by LJ. The groups were
183 94 undertaken in Arabic and the transcripts were then translated from Arabic into English, except
184 95 for the PG group, which was conducted in English. A member of the research team (LJ)
185 96 undertook the translation; a professional translator checked the accuracy of the translation. The
186 97 analysis used a priori and emergent codes; codes were identified independently from the data
187 98 by two researchers (LJ, MW). [19] The codes were then categorised using the HFF. Two coding
188 99 (Supplementary Material) indices were generated based on commonality of codes: one was
189 100 used to code the transcripts of the PG and CPG, while the other was for the pharmacy user
190 101 groups. The coding for each focus group was checked for accuracy by a second researcher (MW,
191 102 SA, or PK). A comparative analysis was then conducted to identify commonality, differences and
192 103 relationships through the themes categorised in the HFF to identify mega themes. [19] This
193 104 study was conducted and reported in accordance with COnsolidated Criteria for Reporting
194 105 Qualitative Studies (COREQ). [20]
201
202

203 **106 RESULTS**
204

205 107 In total, 35 individuals participated across four focus groups and four interviews (Table 1). All
206 108 data collection was undertaken between February and May, 2013. The PG (n=8) comprised
207 109 representatives from several organisations responsible for regulating pharmacists and
208 110 pharmacy practice, as well as pharmacy academics and pharmacy owners. All participants in the
209 111 PG were Saud nationals. The CPG participants were Egyptian (n=3) and Yemeni (n=1).
210
211
212

213 **112 Table 1** Characteristics of participants
214

Focus Groups	Professionals	Community pharmacists		Pharmacy users	
	Focus group	Focus group	Individual Interviews	Female focus group	Male focus group
Total Individuals invited	15	75	5	15	9
Number of participants (male)	8 (7)	4 (4*)	4 (4*)	11 (0)	8 (8)
Age years (SD)	40.6 (7.1)	34.7 (10.6)	37.7 (13.8)	33.5 (5.8)	34 (5.9)
Duration of interaction (minutes)	104	86	19.2 (3) Mean (SD)	62	89

215
216
217
218
219
220 113 Only males are permitted to work in the community pharmacy setting in KSA.
221

222 114 SD Standard deviation
223

224
225
226
227
228
229 115
230 116 The data were categorised into nine categories representing the HFF (Table 2). From these
231 117 categories, seven main themes were identified (Table 3). Example of similarities and differences
232 118 of themes across all groups are presented in (Table 4). The themes are described in the text
233
234
235
236

119 supported by anonymised, verbatim quotes from participants' narratives (which are written in
 120 italics and quotation marks). To illustrate which focus group generated the identified themes,
 121 results are referred to below by the following letters: professionals (PG); community
 122 pharmacist (CPG); female pharmacy users groups (FPG) and male pharmacy users groups
 123 (MPG), followed by a hyphen and the number of the participant, e.g. PG-1 is participant 1 in the
 124 PG, etc. For further quotes in the Supplementary Material.

125 **Table 2** Human Factors and sub-themes identified in the Focus groups

Human factors category	Sub-themes
External factors	Commercial pressure and commercialism Regulations and regulators The healthcare system in Kingdom of Saudi Arabia
Organisational and management factors	Pharmacy owners' and managers' roles Lack of patient database in community pharmacies
Work environment	Pharmacist working hours Type of pharmacy and its effect on medication safety
Team factors	Physician prescribing behaviour Communication between pharmacists and physicians
Individual factors: Pharmacists	Pharmacist competence and clinical skills Pharmacist adherence to law and regulations Pharmacist role as perceived by participants
Task factors	Illegal Supply of prescription-only medication to patients. Medication storage and transportation in community pharmacies Generic substitution
Communication and information exchange	Patient-pharmacist communication Factors affecting communication exchange Type of information requested by patients from pharmacists Patient medication information source Pharmacist versus physician information
Patient	Patient characteristics: risk factors for medication safety problems Patient trust in pharmacists Patient trust in physicians Patient beliefs and perceptions Patients' behaviour Patient role and responsibility towards medication safety
Medication	Medicines associated with the risk Medication availability and shortage Counterfeit medication
Others	Patient experiences with drug-drug interaction and adverse drug events Comparison with other countries regarding practice and quality of medication.

296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354

131 **Table 3** Emergent themes identified

Emergent themes	Sub-themes
Commercialism and commercial pressure on community pharmacies in kingdom of Saudi Arabia	External factors <ul style="list-style-type: none"> • Commercial pressure and commercialism • Healthcare system role in commercialism Organisational and management factors <ul style="list-style-type: none"> • The role of pharmacy owners and managers Work environment <ul style="list-style-type: none"> • Type of pharmacy and its effect on medication safety • Pharmacist working hours • Low salaries Team factors <ul style="list-style-type: none"> • Physician prescribing behaviour Task factors <ul style="list-style-type: none"> • Patient counselling • Generic substitution • Medication storage and transportation Patient factors <ul style="list-style-type: none"> • Patient belief and perception about the business oriented practice • Patient behaviour
Illegal supply of prescription medication by pharmacist	External factors Individual factors: pharmacist Patient factors
Lack of enforcement of regulations	External factors <ul style="list-style-type: none"> • Regulations and regulators Individual factors: pharmacist <ul style="list-style-type: none"> • Pharmacist adherence to law and regulations Patient factors <ul style="list-style-type: none"> • Patient pressure on pharmacists to commit a misconduct Medication <ul style="list-style-type: none"> • Counterfeit medication as consequence
Healthcare system in kingdom of Saudi Arabia	External factors <ul style="list-style-type: none"> • The fragmented healthcare system • Lack of patient database in community pharmacies Organisational and management factors <ul style="list-style-type: none"> • Implementation of technology in community pharmacy
Patient medication-taking behaviour	<ul style="list-style-type: none"> • Self-medication • Sharing medication • Adherence to medication
Patient trust in pharmacists	No subthemes identified
Communication and information exchange	<ul style="list-style-type: none"> • Patient–pharmacist communication • Patient medication information source • Factors affecting communication exchange • Type of information requested by patients from pharmacists • Information received from pharmacist information compared to information received from physician Team factors <ul style="list-style-type: none"> • Communication between pharmacists and physicians

132

133 **Table 4** Example of similarities and differences of themes across all groups

Theme	Professionals	Pharmacists	Pharmacy users	
			Male	Female
Commercialism and commercial pressure on pharmacists.	✓	✓	✓	✓
Self-diagnosing and self-medication.	✓	✓	✓	✓
Lack of enforcement of regulations.	✓	✓	✓	✓
Illegal supply of prescription medication.	✓	✓	✓	✓
Fragmented healthcare system.	✓	✓	✓	
Patient trust in pharmacist.		✓	✓	✓
The primary role of the pharmacist should be as an information provider.		✓	✓	✓
Communication failure between pharmacists and patients.	✓	✓		
The need for information			✓	✓
Perception of pharmacists as salesmen rather than healthcare professionals.			✓	✓
Pharmacy design and its effect on counselling.			✓	✓

134

135 **Commercialism and commercial pressure**

136 Commercialism in community pharmacy practice in KSA emerged as a theme in all groups.
 137 Participants identified factors and consequences of commercialism on patient safety. These
 138 factors are presented here according to the HFF: external; organisational; work environment;
 139 team; task; and patient factors.

140 *External factors*

141 Participants across all groups except the FPG discussed the role of pharmaceutical companies in
 142 creating commercial pressure by paying bonuses to physicians and community pharmacists to
 143 prescribe and dispense certain medications, which may not be needed.

144 *“In our country, the pharmacist gives you the medication that is suitable to him*
 145 *or the medication for which he receives a commission, you go to the*
 146 *pharmacist you say you have a headache he gives you Fevadol instead of*
 147 *Panadol [generic substitute] for example he gives you the medication that suits*
 148 *you, who he is an agent for it or gives him a commission for. Even in clinics, the*
 149 *representative of the company comes to the physician and gives him the new*
 150 *medications with tickets and gifts and the physician prescribes the*
 151 *medications.” (MPG-5)*

152 The PG participants suggested that recent rapid increases in the number of pharmacies,
 153 combined with their proximity to each other, contributed to increased competition between

414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472

154 them. This pressured pharmacists to illegally supply POM to to maintain their business and
155 retain consumers/patients.

156 *“It is not logical that I will not sell the medication without [prescription], while my*
157 *neighbour is selling it without [prescription]. I would go broke.”(PG-2)*

158 The PG participants also suggested that the pharmaceutical industry restricted certain generic
159 medicines to increase sales of newer, more expensive brands, contributing to medication
160 shortages.

161 *“I comment on availability issues. Some of it [is] truly shortages, and some of it is*
162 *[not]. Unfortunately, this is a commercial business. I know some pharmacies will*
163 *not introduce a product without getting fees or getting huge bonuses from the*
164 *company. The company will not be able to sell it that is again with the law how*
165 *far you can enforce the law on community pharmacy?” (PG-4)*

167 *Organisational and managerial factors*

168 Participants in the CPG believed that pressure from owners and managers of community
169 pharmacies contributed to creating a profit-oriented rather than patient-oriented pharmacy
170 practice.

171 *“Maybe he is being pushed by his managers to be money making...”(MPG-3)*

172 *Work environment*

173 The CPG, FPG and MPG perceived community pharmacies owned by commercial companies
174 (also known as chain pharmacies) to be safer than independent pharmacies. They explained
175 that chain pharmacies have more rigorous internal regulatory systems, offer training
176 programmes for the pharmacists and have lower individual workload owing to investment in
177 technology. Interestingly, the public group believed that independent pharmacies are less
178 affected than chain pharmacies by commercial pressures.

180 *“[Chain pharmacies] have a policy that we will not violate the law and the*
181 *patient will find what he wants; this is the mistake of the patient” (CPG-1)*

183 The CPG and MPG participants discussed long working hours and their effect on practice. They
184 believed that the long working hours were related to the owner’s interest in maintaining their
185 profit.

186 *“He has long working hours and that leads many pharmacists to not refresh*
187 *their information, ...there is no role for the Ministry to update your*

473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531

188 *information. For example, the pharmacist (CPG-4) graduated in 1986 and*
189 *necessarily many improvements have taken place since that time.”(CPG-2)*

191 *Team factors*

192 The PG also acknowledged that pharmaceutical companies influence the prescribing behaviour
193 of physicians through advertising and financial incentives, which tends to result in
194 overprescribing.

195 *“The quality of the physician usually they come with very low salaries but*
196 *depending on the commissioning they get from the companies and still they have*
197 *the commission we see the kind of prescription which is very weak even our*
198 *pharmacists discover these mistakes it happens with me a lot so due to this kind*
199 *of this low educated physicians.”(PG-2)*

200 *Task factors*

201 Participants in the pharmacy user groups felt that commercial pressure on pharmacists affected
202 the advice and information provided. They suggested that advice given by the community
203 pharmacists was for marketing purposes and not tailored to patients’ actual needs.

204 *“My problem is always that when I go, they give me the best and the latest on the*
205 *market, that is to say, they do not give me the one appropriate for me. The problem is*
206 *that they do not try to learn whether it is appropriate or not.”(FPG-1)*

207
208 Pharmacists substituting a prescribed branded medication with a different form of the same
209 active substance (generic substitution) was an emerging theme across all groups. The PG stated
210 that the problem is that community pharmacists provide medication alternatives to patients
211 based on financial incentives and commission rather than patient benefit.

212 *“If you go to a pharmacist and you say you have a mild or minor ailment and*
213 *ask for a prescription, you have two products [options] one product will fit*
214 *you, but that does not have a bonus, the other product has a bonus.”(PG-4)*

216 Participants discussed the problem of inappropriate storage conditions for medicines in
217 community pharmacies and warehouses, attributed by some participants in the PG and
218 pharmacy users’ groups to a desire to cut costs.

219 *“It is a matter of saving electricity just like groceries. At night, they*
220 *disconnect the refrigerator containing milk to save electricity, and when*
221 *they come back in the morning, they turn on the electricity.” (MPG-4)*

532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590

223 **Patient factors**

224 On a number of occasions, participants in the PG as well as the pharmacy user groups referred
225 to the way that patients perceive the community pharmacy as a grocery shop.

226 *"We look in KSA at a pharmacy as a store ... It should be a service, not a*
227 *store."*(PG -3)

228 However, perceptions of pharmacists were highly varied amongst participants in the pharmacy
229 user groups. Some considered pharmacists to be salesmen, while others perceived them as
230 healthcare professionals.

231 *"He is interested mainly in collecting money."*(FPG-3)

232
233 *"People think that he is a seller, but he is well qualified in term of education.*
234 *He spent a long time studying and understands drug composition maybe more*
235 *than the physicians."*(FPG -2)

236 Participants in the pharmacy user groups acknowledged that they buy whatever they want from
237 the pharmacy acting as a "consumer."

238 *"As a consumer, I go to the pharmacy and take the antibiotic I want, I can take*
239 *whatever medication I want without prescription."* (MPG-5)

241 **Illegal supply of prescription medication by pharmacists**

242 *External factors*

243 The PG suggested many reasons to explain the illegal supply of POM which they described as a
244 violation of regulations, including patients perceiving medication as a commodity and patients
245 who are stable on medication visiting the community pharmacy to refill their POM without a
246 prescription. In addition, they suggested other "external factors" that were highlighted
247 previously, such as the limited capacity of the healthcare system, the lack of regulation
248 enforcement and commercial pressures.

249 *"...So now you have lack of enforcement of the law, huge pharmacies, huge*
250 *number of non-Saudi pharmacists and you can say there is nobody in*
251 *charge that lead to where people are treating medications as a commodity*
252 *rather than special products that need attention..."*(PG-4)

254 However, such practices were identified as a cause of hospital admission by the PG. Antibiotics
255 were given as an example of medication supplied illegally in all groups, and participants in the
256 CPG provided other examples, such as hypnotics and antidepressants.

591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649

257 *Individual factors: pharmacists*

258 Participants in the CPG acknowledged that they sometimes illegally supply POM and provided
259 justifications for their actions.

260 *"I dispense everything; I am a pharmacist regardless of the laws, when you have a*
261 *patient in front of you needing to be treated it would be difficult especially if the*
262 *patient is poor and needs assistance you do not help him; for humanity"(CPG-4)*
263

264 **Lack of enforcement of regulations**

265 Lack of enforcement of regulations emerged as a theme in all groups. Factors and consequences
266 of lack of enforcement of regulations identified in this study are presented in this section
267 according to the HFF: external; pharmacist and patient.

268 *External factors*

269 Across all groups, participants agreed that the Saudi government issued regulations to uphold
270 the quality of community pharmacy practice. Participants also identified the roles played by
271 different regulatory bodies in inspecting and controlling medication supply. However, they all
272 agreed that governmental regulations are not enforced effectively.

273 *"...There is a complete difference between the law and the reality." (CPG-2)*
274

275 The PG suggested that there were too few governmental inspectors in relation to the large
276 number of community pharmacies. Furthermore, the community pharmacists perceived
277 inspectors to be inadequately trained.

278 *"...The number of inspectors who are supposed to enforce the law have almost*
279 *declined you don't have the same growth in the number of inspectors as you have*
280 *in the number of the pharmacies...so that automatically leads to the lack of*
281 *enforcement of the law so now you have lack of enforcement of the law, huge*
282 *pharmacies, huge number of expatriates pharmacists and you can say there is*
283 *nobody in charge." (PG-4)*
284

285 *Individual factors: pharmacists*

286 Pharmacists' adherence to regulations emerged during the discussion. One participant in the PG
287 group believed that all pharmacists would like to adhere to the law.

288 *"No professional pharmacist will like to break the law..."(PG-4)☒*

289 Conversely, the CPG admitted violating certain pharmacy practice regulations. There were
290 examples of pharmacist violations given in all the focus groups, such as illegal supply of POM,

650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708

291 inappropriate storage conditions of medication, pharmacists working without licence, and
292 supplying medication without a label.

293 *“The air conditioning is not working, the expiry date of the medicine ... also they*
294 *store medicines outside the refrigerator. We found some big problems we saw the*
295 *technician dispensing the medicine they are not allowed to dispense the medication*
296 *also find the pharmacist work without licence this is a big problem in the*
297 *pharmacy.”(PG-8)*

299 *Patients factors*

300 Patients also influence pharmacists’ behaviour in terms of not adhering to regulations due to
301 pressurising pharmacists to illegally supply medications. Participants in the CPG said that they
302 find themselves compelled to supply medication to patients in these situations, despite this
303 being prohibited by law.

304 *“Originally, it is prohibited by the Ministry of Health to dispense antibiotic as a*
305 *strip and if this is done it would be a violation and in case of not dispensing them*
306 *in this form, the patient will go to a second, third and fourth pharmacy until he*
307 *finds what he wants” (CPG-1)*

309 **The healthcare system in Kingdom of Saudi Arabia**

310 Participants in all groups discussed factors related to the healthcare system and their impact on
311 medication safety in Saudi Arabia. These factors are presented here according to the HFF:
312 external and organisational factors.

313 *External factors*

314 The structure of the Saudi healthcare system was an emerging theme. The PG and FPGs
315 discussed the fragmented healthcare system. Patients visiting different physicians for the same
316 medical problem and a lack of continuity in care are the results of the fragmented provision of
317 healthcare that could lead to medication duplication and compromised medication safety.

318 *“For example, the patient went to a physician who prescribed him Amlor*
319 *[Amlopidine] and then went to another physician who prescribed him Amlopine*
320 *[Amlopidine]. He imagined that they are different medications and took both.”*
321 *(CPG-4)*

323 The PG discussed the limited capacity of the healthcare system and its inability to meet the
324 increasing healthcare needs of the population. They suggested that community pharmacies
325 could play a role in caring for patients to minimise the pressure on other healthcare facilities.

709
710
711 326 *“Community pharmacy should work as primary centres ... take for example diabetic*
712 327 *patient whatever the government invest and put amount of money in hospitals and*
713 328 *primary care they will not be able to manage the whole diabetic population. They are*
714 329 *huge [the diabetic population] so if you add hypertensive patients and asthmatic*
715 330 *patient they are huge.”(PG-4)*
716 331

718
719 332 Participants also discussed the lack of a patient database and filing system in community
720 333 pharmacies: they perceived an electronic patient database with relevant medical information
721
722 334 accessible to community pharmacists to be an important factor in medication safety.

723
724 335 *“There should be a special file for each patient in each pharmacy, not only in the*
725 336 *hospital.”(CPG-1)*
726 337

728 338 *Organisational and management factors*

729
730 339 Participants suggested that solving the problem starts with the Saudi Ministry of Health, which
731 340 should establish a national electronic health records database. The need to implement
732 341 technologies such as electronic prescribing and to utilise drug information software, was
733 342 discussed in both the PG and the CPG.

737 343 **Patient medication taking behaviour**

738 344 Patients' accounts of behaviours such as self-medication, sharing medication and adherence to
739 345 medication emerged. Self-medication in the context of this study is the selection and use of
740 346 medicines by individuals to treat self-recognized conditions or symptoms with POM or over the
741 347 counter (OTC) medication. Participants in all groups agreed that self-medication is common in
742 348 KSA.

743
744
745
746
747 349 *“I went to the pharmacy and said [something] and then some medications were*
748 350 *given to me, that is, we are treating ourselves.”(MPG-1)*
749

750
751 351 The MPG proposed several reasons for self-medication such as cultural influences, the
752 352 accessibility of medication, the large number of community pharmacies, and patients' previous
753 353 experiences with a medication.
754 354

755
756
757 355 The CPG highlighted that patients even self-medicate with antidepressants without consulting a
758 356 physician. They were also aware of medication abuse such as the use of steroids for weight gain
759 357 and skin whitening.

768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826

358 *"Most people request Seroxa [antidepressant], and a segment of women take it*
359 *due to marriage pressures. They take psychiatric medicines as a tonic that*
360 *enables them to deal with the community in a better way."*(I-3)
361

362 Sharing medication emerged as a theme across the CPG, FPG and MPG. Participants discussed
363 sharing medication such as vitamins, painkillers and antibiotics with family members: *"As fruits*
364 *in the refrigerator."*(MPG-5)

365 *"Sometimes I think that the factor is economics and he doesn't want to pay for*
366 *something he doesn't want to continue using."*(CPG-1)
367

368 Patients do not adhere to their medications and do not follow instructions provided by
369 pharmacists as participants in the CPG and MPG described.

370 *"frankly, I never completed the period of the course"* (MPG-3)
371

372 The patient's role in medication safety was discussed in all groups, and there was general
373 agreement of the importance of educating patients.

374 **Patient trust in the pharmacist**

375 Patient trust in the pharmacist emerged in the CPG and pharmacy user groups. Participants in
376 the pharmacy user groups identified several factors that affect this trust, such as pharmacists'
377 age, an existing relationship with the patient, provision of advice, pharmacist nationality, and
378 knowledge of the sector in which the pharmacist worked, e.g. governmental or private. Some
379 participants perceived pharmacists having low levels of competence due to their non-Saudi
380 nationality, especially regarding recognising trade names of medication. Another reason for lack
381 of trust was due to the perception that pharmacists are business-oriented rather than patient-
382 oriented.

383 *"He has knowledge; he is old and calm, and he knows that I am coming for a*
384 *consultation. I tell him the physician prescribed this and this. He knows me, and I*
385 *buy some of the things. He knows my face, and he counsels me and gives me*
386 *some of his time. He says, 'no this is that and this is good', and he gives me*
387 *alternatives. He gives me advice. He is next to my home, and I trust his opinion."*
388 (MPG-4)
389

390 There was disagreement in the MPG that providing generic alternatives increases patients' trust
391 in pharmacists. Participants in the CPG identified several factors that cause patients to lose
392 confidence in the pharmacist. For example, when the pharmacist spends more time reading the
393 prescription due to bad physician handwriting or incomplete patient information, which leads

827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885

394 pharmacists to ask the patient more questions. The CPG believed that patients trust physicians
395 more than pharmacists.

396 *"I may receive a prescription in which the age and the diagnosis are not*
397 *mentioned and what is only mentioned is the name. In order to dispense the*
398 *medication, I ask many questions, I ask until I know the meant medication.*
399 *Asking many questions results in the loss of confidence between the patient and*
400 *me. My questions are meaningful since I concentrate on certain points."* (CPG-3)

401 **Communication and information exchange**

402 Pharmacy users and the CPG discussed poor communication between pharmacists and patients,
403 including the question of who should initiate communication.

404 *"What I notice is that they take the prescription and put it on the counter, and that*
405 *is all. They do not even say hello."* (MPG-1)

406 Pharmacy users expressed a need for information about medication and that the primary role of
407 the pharmacist should be as information provider.

409 Barriers to effective communication identified by participants in all groups included language,
410 culture, education, gender, having a third person (family member or friend) assigned by the
411 patient to obtain the medication from the pharmacy, pharmacy layout and pharmacists'
412 workload.

413 *"I came across someone who didn't know whether the medication was for*
414 *constipation or diarrhoea. He said he wanted something for diarrhoea. The*
415 *matter is that he didn't want something for diarrhoea; he wanted something to*
416 *cause diarrhoea. In brief, language has an effect."* (CPG-4)

417 The CPG suggested that patients' ability to access medication information from other sources,
418 such as the internet or friends, and the role of TV advertising, can cause problems when
419 communicating with a patient, as they come to the pharmacy influenced by information from
420 these different sources.

422 *"Patients come to me and say, 'I read that this drug is dangerous'. I ask him,*
423 *'Where did you read that?' and he says, 'The internet.'"* (CPG-3)

424 The CPG also expressed concerns about the patient providing incomplete information or
425 wrongly expressing symptoms to the pharmacist. The PG and MPG agreed on the need for clear
426 and easily comprehensible information about medication in Arabic.

886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944

428 **DISCUSSION**

429 The study identified a range of major medication safety problems in community pharmacy in
430 KSA from a range of perspectives. The factors and circumstances that contribute to these
431 problems are complex and interact with each other.

432 Commonalities existed across groups, and unsurprisingly the PG identified problems at a
433 systemic or regulatory level. For example, all groups discussed the lack of enforcement of
434 regulations. The professionals provided the reasons behind this, debating the role and
435 importance of each organisation involved in pharmacy practice. The community pharmacists
436 discussed the day-to-day problems that pharmacists face in terms of owners, patients and
437 inspectors. The FPG, of whom the majority were mothers, shared their personal experiences
438 with pharmacists and medications in their daily lives. The MPG also focused on regulations and
439 systems and compared current practice in KSA with other countries, such as the UK and USA.

440 Most studies of medication safety in community pharmacy have considered only one aspect of
441 safety, such as dispensing [21], prescribing errors [22-24] or workload [25]. Two studies have
442 adopted holistic approaches to identify medication safety problems. [26,27] Phipps et al.,
443 identified a number of social technical factors consistent with our findings, such as regulatory
444 and legal factors, group norms, trust in pharmacists, profitability versus safety, quality
445 assurance and workspace, and collaboration between prescribers and patients. [27]

446 Commercialisation of pharmacy practice in this study was attributed to corporatisation,
447 increased numbers of pharmacies, the absence of any governmental reimbursement and the
448 lack of enforcement of regulations by regulatory bodies. Subsequently, some pharmacists
449 illegally supply POMs, supply unnecessary medication or provide generic substitution based on
450 profit not patient benefit. Community pharmacies generally operate as private businesses, thus
451 the financial impact of any decisions made by community pharmacists is a concern that could
452 potentially influence the attitude of pharmacists to service provision, for example the reporting
453 of errors. [27] The Saudi pharmaceutical sector is the largest in the Gulf region, and has recently
454 been growing by 4.7% annually. [28] There has been a six-fold increase in the number of
455 community pharmacies in KSA over the past 30 years. [29] This huge market tends to promote
456 the 'corporatisation' of pharmacies, as has happened in the UK, in which there is a change in
457 ownership pattern from individuals to larger pharmacy chains. [30,31] Bush *et al.* describe the
458 impacts – often negative - on the professional autonomy of pharmacists working in these big
459 companies. [30]

945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003

460 This current study suggests that failure to enforce regulations creates an environment in which
461 violations become routine practice. For example, lack of enforcement of regulations has been
462 attributed in this study and others conducted in KSA to the illegal supply of POM. [7-10] There is
463 a lack of studies exploring the association between violations in community pharmacy practice
464 and enforcement of regulations. [32] Lowe and Montagu [33], reviewed regulatory frameworks
465 in 24 low-income countries and many of the challenges described are similar to those identified
466 in this study, particularly in terms of fragmented pharmacy legislation and regulation, and
467 insufficient numbers of inspectors. [33] Two randomized intervention studies reported the
468 effect of enforcement of regulation on pharmacist compliance to regulations and improving
469 services such as giving advice to customers and a decrease in the illegal supply of some
470 medications. [34,35]

471 Self-medication was identified in this study as one factor contributing to medication safety in
472 community pharmacy. Patients who self-medicate usually diagnose and treat themselves based
473 on their own experience or that of family or friends, or information from the media and internet.
474 One reason for self-medication identified here was that patients could not afford or wanted to
475 avoid a physician visit. The main risks from self-medication identified previously include
476 misuse, a potential delay in treating a serious condition, masking of symptoms of a serious
477 condition through the use of a OTC medication, and drug interaction. [36,37] It is a cause for
478 concern that most of the risks previously identified relate to self-medication with OTC
479 medication, while self-medication with POM is present in KSA. [38]

480 Another important factor identified is the fragmented healthcare system in KSA. Healthcare
481 delivery in KSA occurs in 'mixed market' systems, with care delivered both by government and
482 private sector providers. [39,40] This allows patients to obtain healthcare from multiple
483 healthcare providers, which has been associated with a number of medication safety problems,
484 including duplicate interventions [41], multiple prescriptions, exposure to potential drug
485 interactions [42], and high costs for patients and the government. [43,44] Given there are no
486 patient medication records in Saudi community pharmacies, pharmacists will supply the
487 prescribed medication to patients not knowing their other medication, potentially leading to
488 medication duplication due to multiple prescriptions from multiple doctors.

489 The illegal supply of POM has been reported in many developing countries such as Mexico,
490 China and also in other countries in the Middle East. [45-47] The main reasons identified in KSA
491 were financial interests and the lack of enforcement of regulations. [7,8,11] Pharmacists in this
492 current study admitted to the illegal supply of POM and provided several justifications, which
493 were similar to findings from a qualitative study in India [48], that illegal supply of POMs is a

1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062

494 form of “social work” to help poor patients who cannot afford a physician’s visit. The Indian
495 study also cited commercial interest and the lack of pharmacist knowledge as reasons for this
496 behavior.[48]

497 The lack of communication between pharmacists and patients was identified as a medication
498 safety problem. The importance of establishing two-way communication in identifying [49] and
499 preventing ADEs [50,51] has been previously documented.

500 An important determinant in establishing a relationship with a pharmacist identified in this
501 study is trust in the pharmacist.[52] Participants were suspicious of pharmacists’ motives and
502 their interest in profit rather than patient care. This is consistent with the findings of a study in
503 Ireland. [53]

504 Strategies to target these factors and develop systems that ensure safe use of medication within
505 community pharmacies are needed at different levels.

506 **Strength and limitations of the study**

507 The study findings identified several categories of HFF that are relevant to the community
508 pharmacy setting and provide a deeper understanding of community pharmacy practice,
509 including reasons for specific behaviours, such as the illegal supply of POM. Another strength of
510 the study is that all stakeholders were represented except general medical practitioners.

511 KSA is socially and culturally unique. As such, some factors identified in the current study may
512 not apply elsewhere. However, many factors identified are likely to have resonance in many
513 countries, for example pharmacist workload. [25] The number of participants in the CPG was
514 small, due to the long working hours of community pharmacist. Supplementary telephone
515 interviews helped to achieve data saturation; no new themes emerged in the telephone
516 interviews. [54]

517 Participants were recruited from Riyadh, the capital of KSA, and opinions might not represent
518 those of people across KSA. For example, problems relating to non-Arabic speakers may not be
519 present in more rural areas. More than six million people live in Riyadh, 40% of whom are non-
520 Saudi; this percentage is not the same in other regions. [55] Lastly the majority of participants
521 had a college education, so less educated individuals were under-represented.

522 **CONCLUSION**

523 Community pharmacy has been shown in this study to be a complex system involving many
524 interacting factors that influence medication safety. These factors were identified and

1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121

525 categorised using the Human Factors Framework. Commercial pressures on the community
526 pharmacy sector and community pharmacists, a failure to enforce regulations, the fragmented
527 healthcare system and self-medication, are all factors that contribute to medication safety
528 problems. Strategies are needed at different levels to target these factors and develop systems
529 that ensure safe use of medication within community pharmacies.

530

531 **Acknowledgments**

532 The authors would like to thank the participants in the study. We also thank the Saudi Food and
533 Drug Administration and the Child Care Association in KSA for providing venues to conduct the
534 PG and FPG events.

535 **Contributors**

536 LA, MW, SA and PK were involved in all stages of the study. LA drafted the article, and all
537 authors including KM and HF were involved in critical revisions and approved the final version.

538 **Competing Interests**

539 None

540 **Funding statements**

541 This research project was supported by a grant from the “Research Centre of Female Scientific
542 and Medical Colleges”, Deanship of Scientific Research, King Saud University.

543 **Ethical approval**

544 The College Ethics Review Board, University of Aberdeen, UK

545 **Data sharing statement**

546 Audiotapes, notes and unpublished data from this study are securely stored and only available
547 to Lobna Al Juffali.

548

REFERENCES

- (1) World Health Organisation,. Safer Primary care: A Global Challenge. WHO/IER/PSP/2012.16.Geneva. 27-28 February 2012; Available at: http://www.who.int/patientsafety/summary_report_of_primary_care_consultation.pdf. Accessed May/26, 2016.
- (2) Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. *N Engl J Med* 2003;348(16):1556-1564.
- (3) Teinilä T, Halmepuro-Jaatinen S, Yrityks K, et al. Adapting the US institute of Safe Medication Practices' Medication safety Self assessment tool for community pharmacies in Finland. *Int J Pharm Pract* 2012;20:15-24.
- (4) Al-Olah YH, Al Thiab KM. Admissions through the emergency department due to drug-related problems. *Ann Saudi Med* 2008 Nov-Dec;28(6):426-429.
- (5) Al-Arifi M, Abu-Hashem H, Al-Meziny M, et al. Emergency department visits and admissions due to drug related problems at Riyadh military hospital (RMH), Saudi Arabia. *Saudi Pharm J* 2014 1;22(1):17-25.
- (6) Aljadhey H, Mahmoud MA, Hassali M, et al. Challenges to and the future of medication safety in Saudi Arabia: a qualitative study. *Saudi Pharm J* 2014;22(4):326-332.
- (7) Bin Abdulhak A, Al Tannir M, Almansor M, et al. Non prescribed sale of antibiotics in Riyadh, Saudi Arabia: A Cross Sectional Study. *BMC Public Health* 2011;11(1):538.
- (8) Al-Mohamadi A, Badr A, Bin Mahfouz L, et al. Dispensing medications without prescription at Saudi community pharmacy: extent and perception. *Saudi Pharm J* 2013 1;21(1):13-18.
- (9) Bahnassi A. Pharmacists views and practices in regard to sales of antibiotics without a prescription in Madinah, Saudi Arabia. *J Patient Saf* 2016;12(3):159-164.
- (10) Bahnassi A. Do no harm: the role of community pharmacists in regulating public access to prescription drugs in Saudi Arabia. *Int J Clin Pharm* 2015.
- (11) Bawazir SA. Prescribing pattern at community pharmacies in Saudi Arabia. *Int Pharm J* 1992;6(5):222-223.
- (12) Carayon P, Xie A, Kianfar S. Human factors and ergonomics as a patient safety practice. *BMJ Qual Saf* 2014 Mar;23(3):196-205.
- (13) Taylor-Adams S, Vincent C, Street P. Systems analysis of clinical incidents: the London protocol. *Clin Risk* 2004;10(6):211-220.
- (14) Carayon P, Schoofs Hundt A, Karsh B, et al. Work system design for patient safety: the SEIPS model. *Qual Saf Health Care* 2006;15:i50-i58.
- (15) Lawton R, McEachan RR, Giles SJ, et al. Development of an evidence-based framework of factors contributing to patient safety incidents in hospital settings: a systematic review. *BMJ Qual Saf* 2012 May;21(5):369-380.

- 1181
1182
1183 585 (16) World Health Organisation. The world health report 2000. Health systems: improving
1184 586 performance. Geneva. 2000; Available at: <http://www.who.int/whr/2000/en/>. Accessed May/25, 2016.
1185
- 1186 587 (17) Henriksen K, Dayton E, Keyes MA, et al. Understanding adverse events: a human factors
1187 588 framework. In: Hughes RG, editor. Patient Safety and Quality: An Evidence-Based Handbook for
1188 589 Nurses US: Rockville (MD): Agency for Healthcare Research and Quality; 2008. p. 1-17.
1189
- 1190 590 (18) Vincent C, Taylor-Adams S, Stanhope N. Framework for analysing risk and safety in clinical
1191 591 medicine. *BMJ* 1998;316(7138):1154-1157.
1192
- 1193 592 (19) Harding J. Using codes to analyse an illustrative issue. Qualitative data analysis from start to
1194 593 finish: Sage; 2013. p. 81-106.
1195
- 1196 594 (20) Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):
1197 595 a 32-item checklist for interviews and focus groups. *Int J Qual Health C* 2007;19(6):349-357.
1198
- 1199 596 (21) Teinilä T, Grönroos V, Airaksinen M. A system approach to dispensing errors: a national study
1200 597 on perceptions of the Finnish community pharmacists. *Pharm World Sci* 2008;30(6):823-833.
1201
- 1202 598 (22) Sánchez, Alina de las Mercedes Martínez. Medication errors in a Spanish community pharmacy:
1203 599 nature, frequency and potential causes. *Int J Clin Pharm* 2013;35(2):185-189.
1204
- 1205 600 (23) Knudsen P, Herborg H, Mortensen AR, et al. Preventing medication errors in community
1206 601 pharmacy: frequency and seriousness of medication errors. *Qual Saf Health Care* 2007
1207 602 Aug;16(4):291-296.
1208
- 1209 603 (24) Sandars J, Esmail A. The frequency and nature of medical error in primary care: understanding
1210 604 the diversity across studies. *Fam Pract* 2003 Jun;20(3):231-236.
1211
- 1212 605 (25) Lea V, Corlett S, Rodgers R. Workload and its impact on community pharmacists' job
1213 606 satisfaction and stress: a review of the literature. *Int J Pharm Pract* 2012;20(4):259-271.
1214
- 1215 607 (26) Ashcroft D, Morecroft C, Parker D, et al. Patient safety in community pharmacy: understanding
1216 608 errors and managing risk. London: Royal Pharmaceutical Society of Great Britain; 2005.
1217
- 1218 609 (27) Phipps DL, Noyce PR, Parker D, et al. Medication safety in community pharmacy: a qualitative
1219 610 study of the sociotechnical context. *BMC Health Serv Res* 2009;9(1):158.
1220
- 1221 611 (28) The Economist Intelligence Unit – Saudi Arabia: Healthcare and Pharmaceuticals Report. *The*
1222 612 *Economist Intelligence Unit* August 2012.
1223
- 1224 613 (29) Ministry of Health, Saudi Arabia. Key indicators-Health indicators for 1435H. 2014; Available
1225 614 at: <http://www.moh.gov.sa/Ministry/Statistics/book/Documents/1435.pdf>. Accessed May/24, 2016.
1226
- 1227 615 (30) Bush J, Langley C, Wilson K. The corporatization of community pharmacy: implications for
1228 616 service provision, the public health function, and pharmacy's claims to professional status in the
1229 617 United Kingdom. *Res Social Adm Pharm* 2009;5(4):305-318.
1230
- 1231 618 (31) Chakraborty A. How boots Rouge, *The Guardian*, 13 April. 2016; Available at:
1232 619 <https://www.theguardian.com/news/2016/apr/13/how-boots-went-rogue>. Accessed 1 November, 2016.
1233
- 1234 620 (32) Goel P, Ross-Degnan D, Berman P, et al. Retail pharmacies in developing countries: a behavior
1235 621 and intervention framework. *Soc Sci Med* 1996;42(8):1155-1161.
1236
1237
1238
1239

1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298

622 (33) Lowe RF, Montagu D. Legislation, regulation, and consolidation in the retail pharmacy sector in
623 low-income countries. *South Med Rev* 2009;2:35-44.

624 (34) Stenson B, Syhakhang L, Lundborg CS, et al. Private pharmacy practice and regulation. *Int J*
625 *Technol Assess Health Care* 2001;17(4):579-589.

626 (35) Chalker J, Ratanawijitrasin S, Chuc N, et al. Effectiveness of a multi-component intervention on
627 dispensing practices at private pharmacies in Vietnam and Thailand—a randomized controlled trial.
628 *Soc Sci Med* 2005;60(1):131-141.

629 (36) Hughes C, McElnay J, Fleming G. Benefits and risks of self medication. *Int J Pharm Pract*
630 2001;24(14):1027-1037.

631 (37) Ruiz ME. Risks of self-medication practices. *Curr Drug Saf* 2010;5(4):315-323.

632 (38) Asseray N, Ballereau F, Trombert-Paviot B, et al. Frequency and Severity of Adverse Drug
633 Reactions Due to Self-Medication: A Cross-Sectional Multicentre Survey in Emergency Departments.
634 *Drug Saf* 2013;36(12):1159-1168.

635 (39) Al -Yousuf M, Akerele TM, Al-Mazrou YY. Organization of the Saudi health system. *East*
636 *Mediterr Health J* 2002;8:645-653.

637 (40) Almalki M, Fitzgerald G, Clark M. Health care system in Saudi Arabia: an overview/Aperçu du
638 système de santé en Arabie saoudite. *East Mediterr Health J* 2011;17(10):784.

639 (41) Kasteler J, Kane RL, Olsen DM, Thetford C. Issues underlying prevalence of" doctor-shopping"
640 behavior. *J Health Soc Behav* 1976:328-339.

641 (42) Lo AY, Hedley AJ, Pei GK, et al. Doctor-shopping in Hong Kong: implications for quality of
642 care. *Int J Qual Health Care* 1994 Dec;6(4):371-381.

643 (43) Demers M. Frequent users of ambulatory health care in Quebec: the case of doctor-shoppers. *Can*
644 *Med Assoc J* 1995 Jul 1;153(1):37-42.

645 (44) Shin J, Choi N, Jung S, et al. Overlapping medication associated with healthcare switching
646 among Korean elderly diabetic patients. *J Korean Med Sci* 2011;26(11):1461-1468.

647 (45) Casner PR, Guerra LG. Purchasing prescription medication in Mexico without a prescription.
648 The experience at the border. *West J Med* 1992 May;156(5):512-516.

649 (46) Pan H, Cui B, Zhang D, et al. Prior knowledge, older age, and higher allowance are risk factors
650 for self-medication with antibiotics among university students in southern China. *PloS one*
651 2012;7(7):e41314.

652 (47) Morgan DJ, Okeke IN, Laxminarayan R, et al. Non-prescription antimicrobial use worldwide: a
653 systematic review. *Lancet Infect Dis* 2011;11(9):692-701.

654 (48) Kotwani A, Wattal C, Joshi P, et al. Irrational use of antibiotics and role of the pharmacist: an
655 insight from a qualitative study in New Delhi, India. *J Clin Pharm Ther* 2012;37(3):308-312.

656 (49) Viktil KK, Blix HS, Moger TA, et al. Interview of patients by pharmacists contributes
657 significantly to the identification of drug-related problems (DRPs). *Pharmacoepidemiol Drug Saf*
658 2006;15(9):667-674.

1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357

659 (50) Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing
660 adverse drug events after hospitalization. *Arch Intern Med* 2006;166(5):565-571.

661 (51) Karapinar-Carkit F, Borgsteede SD, Zoer J, et al. Medication Safety: Effect of Medication
662 Reconciliation with and Without Patient Counseling on the Number of Pharmaceutical Interventions
663 Among Patients Discharged from the Hospital. *Ann Pharmacother* 2009;43(6):1001-1010.

664 (52) AlGhurair SA, Simpson SH, Guirguis LM. What elements of the patient–pharmacist relationship
665 are associated with patient satisfaction. *Patient Prefer Adher* 2012;6(1):663-676.

666 (53) Hargie O, Morrow N, Woodman C. Consumer perceptions of and attitudes to community
667 pharmacy services. *Pharm J* 1992;249:688-691.

668 (54) Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? Operationalising
669 data saturation for theory-based interview studies. *Psychol Health* 2010;25(10):1229-1245.

670 (55) Central Department of Statistics & Information, Ministry of Economy and Planning, Saudi
671 Arabia. Annual Statistical Yearbook, 50. 2014; Available at: <http://www.stats.gov.sa/en/1163>.
672 Accessed May/25, 2016.

673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688

1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416

689 **Supplementary material**

690 **Appendix A**

691 **Topic Guide for focus group (Pharmacy user's)**

692

693 **Questions to be addressed during the focus group**

- a. What does medication safety mean to you?
Probes: Your personal experience of problems (adverse effect reactions)

- b. What medicines are safe?
Probes: Why do you think they are safe?

Probes: when you are familiar with a medicine does this makes it safe? How is that?

- c. What medicines do you think are associated with risk?
Probes: Why do you think they are unsafe?

- d. What medical conditions are most likely to cause problems with medicines?

- e. What patients are most at risks from medication?
Probes: Age, Gender, pregnant women, lactating women, etc

- f. What are the main problems that you can encounter in a community pharmacy in terms of medication safety?

- g. How could community pharmacists help people with their medicines?
Probes: your suggestions

- h. Any comments

710

1417
1418
1419 711 **Topic Guide for focus group (Professionals)**
1420

1421 712
1422

1423 713 **Questions to be addressed during the focus group**
1424

1425
1426 714 a. What are the main medication safety concerns associated with medicines supplied
1427
1428 715 from community pharmacies in Saudi Arabia?

1429
1430 716 Probes: Identify the problems and give examples from their point of view and experience.
1431

1432
1433 717 b. Who are the patients most at risk from medication safety problems?

1434
1435 718 Probes: what are the medical conditions that have the highest risk to the patient?

1436
1437 719 Probes: who are the population who are at most risk (age, gender, etc)?
1438

1439
1440 720 c. What types of medication are associated with safety problems in community
1441
1442 721 pharmacy?

1443
1444 722 d. What are the factors that contribute to these problems?

1445
1446 723 e. How can community pharmacists prevent and manage these problems?

1447
1448 724 f. What other agencies, organisations could help to improve medication safety with
1449
1450 725 medicines supplied from community pharmacies?

1451
1452 726 Probes: How could this is achieved?
1453

1454
1455 727 g. Any other comments
1456

1457 728
1458

1459 729
1460

1461 730
1462

1463 731
1464

1465 732
1466

1467 733
1468

1469 734
1470

1471
1472

1473
1474

1475

1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534

735 **Appendix B**

736 **Coding index (expert and community pharmacist)**

737 **1. New prescription**

738 1.1 Refill of a prescription medication

739 1.1.1 With a prescription

740 1.1.2 Without a prescription

741 1.2 Self-medication

742 1.2.1 Internet

743 1.2.2 TV/ Advertisement

744 1.2.3 Family, Friends, neighbours

745 1.2.4 Based on previous experience

746
747 **2. Medication use process**

748 2.1 Prescribing

749 2.1.1 Prescriber

750 2.1.1.1 Lack of knowledge

751 2.1.1.2 Failure to communicate between pharmacist and prescriber

752 2.1.1.3 Unethical prescribing practices/violation of the law

753 2.1.2 Prescription

754 2.1.2.1 Prescription incomplete information or ambiguous

755 2.1.2.2 Handwriting

756 2.1.2.3 Prescribing error

757 2.2 Dispensing

758 2.2.1 Patient pressure to supply medication

759 2.2.2 Incomplete patient information

760 2.2.2.1 Patient medical history

761 2.2.2.2 Medication record

762 2.2.3 Dilemma between patient care and money (commercial pressure)

763 2.2.4 Labelling

764 2.2.5 Illegal supply of medications

765 2.2.5.1 Factors that contribute to illegal supply of medication

766 2.2.5.2 Common medications supplied without a prescription

767 2.2.5.3 consequences of supplying medication without prescription

768 2.2.6 Generic substitution

769 2.3 Pharmacist-patient communication

770 2.3.1 Language

771 2.3.2 Literacy

772 2.3.3 Cultural considerations

773 2.3.4 Third party communicating patient information (family member or

774 2.3.5 Inaccurate information (self-diagnosis)

775
776 2.4 Administration (Medication taking behaviour)

777 2.4.1 Sharing medication

778 2.4.2 Adherence

1535			
1536			
1537	779	2.4.3	Drug abuse
1538	780	2.4.4	Drug misuse
1539	781		
1540	782	2.5	Monitoring
1541	783	2.5.1	No follow up
1542	784	2.5.2	Reasons for no follow up
1543	785	2.5.2.1	No computer system
1544	786	2.5.2.2	Others
1545	787		
1546	788	3.	Medication
1547	789	3.1	High alert medication
1548	790	3.1.1	Analgesics
1549	791	3.1.2	NSAIDS
1550	792	3.1.3	Antibiotics
1551	793	3.1.4	Cortisone
1552	793	3.1.4	Cortisone
1553	794	3.1.5	Control medication
1554	795	3.1.6	Psychotherapeutic agents
1555	796	3.1.7	Thyroxine
1556	797	3.1.8	Weight management agents
1557	797	3.1.8	Weight management agents
1558	798	3.1.9	Minoxidil
1559	799	3.1.10	Vitamins
1560	800	3.1.11	Hormonal replacement therapy
1561	801	3.1.12	Warfarin
1562	802	3.2	Other related medication problems
1563	803	3.2.1	Medications with unimproved indications
1564	804	3.2.2	Look alike, sound like medications
1565	804	3.2.2	Look alike, sound like medications
1566	805	3.2.3	Counterfeit medications
1567	806	3.2.4	Expiration date
1568	807	3.2.5	Bar coding
1569	808	3.2.6	Pricing
1570	809	3.2.7	Medication shortage and availability
1571	810		
1572	811	3.3	Herbal medication
1573	811	3.3	Herbal medication
1574	812	3.4	Medication distribution
1575	813	3.4.1	Transportation
1576	814	3.4.2	Storage
1577	815	3.5	Medication related problem concerning patient outcome
1578	816	3.5.1	Duplication of therapy
1579	817	3.5.2	Adverse drug effects
1580	818	3.5.3	Dosage regimen
1581	818	3.5.3	Dosage regimen
1582	819	3.5.3.1	Dose too high
1583	820	3.5.3.2	Dose too low
1584	821	3.5.4	Drug interaction
1585	822	4.	Patient
1586	823	4.1	Patient at risk of medication safety problems
1587	824	4.1.1	Patient with chronic diseases
1588	825	4.1.2	Patient with Allergies
1589	826	4.1.3	Patients with poly pharmacy
1590	827	4.1.4	Gender
1591			
1592			
1593			

1594		
1595		
1596	828	4.1.4.1 Female
1597	829	4.1.4.2 Male
1598	830	4.1.5 Age
1599	831	4.15.1 Paediatric
1600	832	4.15.2 Geriatric
1601	833	4.1.6 Education
1602	834	4.1.7 Language
1603	835	4.1.8 Patients with no insurance
1604	836	4.2 Patient /public awareness of medication safety
1605	837	4.3 Patient perception and attitude towards healthcare professional roles
1606	838	4.3.1 Physician
1607	839	4.3.2 Pharmacist
1608		
1609	840	5 Pharmacist
1610	841	5.1 Scientific knowledge of pharmacist
1611	842	5.2 Continuing education/ training
1612	843	5.3 The quality of practice/unprofessional practice
1613	844	5.4 Nationality
1614	845	5.5 Pharmacist assessment/ licensing
1615	846	5.6 Working hours
1616	847	5.7 Stress
1617	848	5.8 Fatigue
1618	849	5.9 Salary
1619	850	5.10 Pharmacist perception of their role
1620	851	5.10.1 Compounding
1621	852	5.10.2 Providing clinical services
1622	853	5.10.3 Other
1623		
1624	854	6 Pharmacy
1625	855	6.1 Reimbursement for pharmacy
1626	856	6.2 Specialised pharmacy for each population (disease)
1627	857	6.3 Type of pharmacy
1628	858	6.3.1 Independent
1629	859	6.3.2 Chain pharmacy
1630	860	6.4 Location ,distribution and number
1631	861	6.5 Pharmacy owners/managers
1632	862	6.6 The use of technology
1633	863	6.6.1 Patient databases
1634	864	6.6.2 Drug information software's
1635		
1636	865	7 Organisations and systems
1637	866	7.1 Regulators
1638	867	7.1.1 Role of the Ministry of Health
1639	868	7.1.2 Role of Saudi Food and Drug Authority
1640	869	7.1.3 Role of other organisations
1641	870	7.2 Role of Universities
1642	871	7.3 Pharmaceutical companies and manufactures
1643	872	7.4 Accreditation
1644	873	7.5 Punishing and rewarding system
1645	874	7.6 International Organization for Standardization
1646	875	7.7 Regulation for pharmacy practice
1647		
1648		
1649		
1650		
1651		
1652		

1653		
1654		
1655	876	7.7.1 The availability of regulation
1656	877	7.7.2 Lack of enforcement of regulation
1657		
1658	878	7.8 Inspectors
1659	879	7.8.1 The qualifications of inspectors
1660	880	7.8.2 Number of inspectors
1661		
1662	881	7.8.3 Relationship between pharmacist and inspectors
1663	882	7.9 Insurance
1664		
1665	883	7.10 Patient filling system
1666		
1667	884	8 Commercial pressure
1668		
1669	885	
1670		
1671		
1672	886	
1673		
1674	887	
1675		
1676		
1677	888	
1678		
1679		
1680	889	
1681		
1682	890	
1683		
1684		
1685	891	
1686		
1687		
1688	892	
1689		
1690		
1691	893	
1692		
1693	894	
1694		
1695		
1696	895	
1697		
1698		
1699	896	
1700		
1701		
1702	897	
1703		
1704	898	
1705		
1706		
1707	899	
1708		
1709		
1710		
1711		

1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770

900 Coding index (Pharmacy users)

- 901 **1 Patient** (related to the patient characteristics and others)
- 902
- 903 **1.1 Patient at risk of medication safety problems**
- 904 **1.1.1 Patient with chronic diseases**
- 905 **1.1.2 Patient with Allergies**
- 906 **1.1.3 Patients with serious operations**
- 907 **1.1.4 Patients with poly pharmacy**
- 908 **1.1.5 Patients with kidney problems**
- 909 **1.1.6 Patients with liver problems**
- 910 **1.1.7 Gender**
- 911 **1.1.7.1 Female**
- 912 **1.1.7.1.1 Pregnant**
- 913 **1.1.7.1.2 Hormones**
- 914 **1.1.7.1.3 More prone to disease**
- 915 **1.1.7.2 Male**
- 916 **1.1.8 Age**
- 917 **1.1.8.1 Paediatric**
- 918 **1.1.8.2 Geriatric**
- 919 **1.1.8.2.1 Bed ridden patients**
- 920 **1.1.9 Education**
- 921 **1.1.9.1 Patients**
- 922 **1.1.9.2 Care givers**
- 923
- 924 **1.2 Patients perceptions and believes**
- 925 **1.2.1 The medication is safe if it is written in the package insert that it is safe**
- 926 **1.2.2 Effective medicine are prescribed by the physician**
- 927 **1.2.3 Medications prescribe by the physician are safe**
- 928 **1.2.4 Illegal supply of medication by pharmacist are risky**
- 929 **1.2.5 Community pharmacies are not safe**
- 930 **1.2.6 Intervention of pharmacist is a must**
- 931 **1.2.7 Antibiotics has to be used as directed**
- 932 **1.2.8 Certain disease must be treated and others not important**
- 933 **1.2.9 Pharmacies are shops, groceries (for business)**
- 934 **1.2.10 Patient risk perception**
- 935 **1.2.10.1 Based on information provided**
- 936 **1.2.10.2 According to setting (hospital vs. community pharmacy)**
- 937 **1.2.10.3 Different routes are associated with different risks**
- 938
- 939
- 940 **1.3 Patient /public awareness of medication safety**
- 941 **1.3.1 Patient responsibility and role**
- 942 **1.3.2 Patient awareness of regulations**
- 943 **1.3.3 Awareness of the importance of the correct dosage form**
- 944 **1.3.4 Awareness of the importance of the medication history**
- 945 **1.3.5 Awareness about asking about allergies**
- 946 **1.3.6 Awareness about the importance of asking about other medication**
- 947
- 948 **1.4 Patient perception and attitude towards healthcare professionals roles**
- 949 **1.4.1 Differentiate between health care professionals role**
- 950 **1.4.2 Physicians**
- 951 **1.4.2.1 Blame physician**

1771		
1772		
1773	952	1.4.2.2 Physician is always right
1774	953	1.4.3 Pharmacist
1775	954	1.4.3.1 Role of the pharmacist
1776	955	1.4.3.2 Perceive a positive role
1777	956	1.4.3.3 Perceive a negative role
1778	957	1.4.3.4 Based on nationality
1779	958	1.4.3.5 Blame pharmacist
1780	959	
1781	960	1.5 Patient behaviour
1782	961	1.5.1 Self medication
1783	962	1.5.2 Sharing medication
1784	963	1.5.3 Addiction/dependence problem
1785	964	1.5.4 Inappropriate medication use
1786	965	1.5.5 Do not follow instruction
1787	966	1.5.6 Patient pressure to supply medication
1788	967	1.5.7 Noncompliance
1789	968	1.5.8 Patients do not buy medication from pharmacist they do not know
1790	969	1.5.9 Patient test the pharmacist
1791	970	1.5.10 Patient do not want to decide for their selves
1792	971	1.5.11 Trust
1793	972	1.5.11.1 Patients trust pharmacist
1794	973	1.5.11.2 Based on knowledge
1795	974	1.5.11.3 Based on nationality
1796	975	
1797	976	2 Information and communication
1798	977	2.1 Sources of information
1799	978	2.1.1 Pharmacist
1800	979	2.1.2 Physician family, neighbours and friends
1801	980	2.1.3 Internet
1802	981	2.1.4 Package insert
1803	982	2.1.5 Advertisement
1804	983	2.1.6 Media
1805	984	
1806	985	2.2 Type of information requested
1807	986	2.2.1 What it is
1808	987	2.2.2 Direction of use
1809	988	2.2.3 Dose
1810	989	2.2.4 Dosage form
1811	990	2.2.5 What it is taken for
1812	991	2.2.6 Drug interaction
1813	992	2.2.7 Side effects
1814	993	2.2.8 Alternative
1815	994	2.2.9 Cost
1816	995	2.3 Quality of information provided
1817	996	2.3.1 Lack of information
1818	997	2.3.2 Wrong information
1819	998	2.3.3 Understandable information
1820	999	2.3.4 Not patient centred
1821	1000	2.3.5 Conflicting information
1822	1001	2.3.5.1 Between pharmacists
1823	1002	2.3.5.2 Between pharmacist and physician
1824	1003	2.3.6 Communication between pharmacist and patient
1825	1004	2.3.6.1 Information exchange
1826	1005	2.3.6.1.1 Pharmacist start asking
1827		
1828		
1829		

1830		
1831		
1832	1006	2.3.6.1.2 Patient start asking
1833	1007	2.3.6.2 Ask about the history
1834	1008	2.3.6.3 Allergic reaction
1835	1009	2.3.6.4 Other medication
1836	1010	2.3.6.5 Privacy
1837	1011	2.3.6.6 Time
1838	1012	2.3.6.7 Third party communicating patient information (family member or other)
1839	1013	2.3.7 Communication between physician and patient
1840	1014	2.3.7.1 Insufficient information gathering from patient
1841	1015	
1842	1016	
1843	1017	3 Comparison between Saudi Arabia community pharmacy practice and other countries
1844	1018	3.1 Pharmacy setting
1845	1019	3.2 Pharmacist practice
1846	1020	3.3 Medication
1847	1021	
1848	1022	4 Medication
1849	1023	
1850	1024	4.1 Medication composition
1851	1025	4.2 Generic substitution
1852	1026	4.3 Illegal supply of medications
1853	1027	4.3.1 Factors that contribute to illegal supply of medication
1854	1028	4.3.2 Consequences of illegal supply
1855	1029	4.3.3 Illegal supply is safe
1856	1030	4.3.4 Illegal supply is risky
1857	1031	4.3.5 Medication that are illegally supplied
1858	1032	4.4 Safe Medication
1859	1033	4.4.1 Paracetamol products
1860	1034	4.4.2 Mebo
1861	1035	4.4.3 Otrivin
1862	1036	4.4.4 Nasonex
1863	1037	4.4.5 Cosmetics
1864	1038	4.4.6 Vitamin C
1865	1039	4.4.7 Aspirin
1866	1040	4.5 Risky medication
1867	1041	4.5.1 Contraceptives
1868	1042	4.5.2 Antibiotics
1869	1043	4.5.3 Cortisone
1870	1044	4.5.4 Asthma medication
1871	1045	4.5.5 Roaccutane
1872	1046	4.5.6 Whiting drugs
1873	1047	4.5.7 Psychotherapeutic agents
1874	1048	4.5.8 Thyroxin
1875	1049	4.5.9 Weight management agents
1876	1050	4.5.10 Creams
1877	1051	4.5.11 Multivitamins
1878	1052	4.5.12 Hormonal replacement therapy
1879	1053	4.5.13 Antihistamine
1880	1054	4.5.14 Medication for cough
1881	1055	4.5.15 Performance enhancing medication in sport
1882	1056	
1883	1057	4.6 Other related medication problems
1884	1058	4.6.1 Medications with unimproved indications
1885	1059	4.6.2 Sources of medication
1886		
1887		
1888		

1889		
1890		
1891	1060	4.6.3 Availability of medication
1892	1061	4.6.4 Accessibility of medication
1893	1062	4.6.5 Quality of medication
1894	1063	4.6.6 Quantity of medication
1895	1064	4.6.7 Compounding
1896	1065	4.6.8 Counterfeit medications
1897	1066	4.6.9 Expiration date
1898	1067	4.6.10 Bar coding
1899	1068	4.6.11 Pricing
1900	1069	4.7 Herbal medication
1901	1070	4.8 Drug abuse
1902	1071	4.9 Drug misuse
1903	1072	4.10 Medication Storage
1904	1073	4.10.1 Dosage regimen
1905	1074	4.10.1.1 Dose
1906	1075	4.10.1.2 Dosage form
1907	1076	4.11 Medication related problem concerning patient outcome
1908	1077	4.11.1 Duplication of therapy
1909	1078	4.11.2 Adverse drug effects
1910	1079	4.11.3 Medication error
1911	1080	4.11.4 Allergy
1912	1081	4.11.5 Drug interaction
1913	1082	2.11.5.1 Consequences of drug interaction
1914	1083	
1915	1084	5 Pharmacist (related to the pharmacist characteristics and others)
1916	1085	5.1 Lack of knowledge
1917	1086	5.2 The quality of practice/unprofessional practice
1918	1087	5.3 Nationality
1919	1088	5.4 Working hours
1920	1089	5.5 Shortage of staff
1922	1090	5.6 Fraud certificate
1923	1091	5.7 unqualified pharmacist
1924	1092	5.8 Pharmacist busy
1925	1093	5.9 Pharmacist should be proactive
1926	1094	5.10 Ethics and morality
1927	1095	5.11 Stress
1928	1096	5.12 Salary
1929	1097	5.13 Commercial pressure
1930	1098	5.14 Primary role is a n information provider
1932	1099	5.15 Identify drug interaction
1933	1100	5.16 Pharmacovigilance
1934	1101	
1935	1102	6 Pharmacy
1936	1103	
1937	1104	6.1 Pharmacies are accessible
1938	1105	6.2 Sell everything
1939	1106	6.3 Source of medication when government cannot supply enough
1940	1107	6.4 Location and distribution
1941	1108	6.5 Pharmacy owners/managers
1942	1109	6.6 Other personal working in pharmacy
1943	1110	6.7 Pharmacy design and arrangement
1944		
1945		
1946		
1947		

1948	
1949	
1950	1111
1951	1112
1952	1113
1953	1114
1954	1115
1955	1116
1956	1117
1957	1118
1958	1119
1959	1120
1960	1121
1961	1122
1962	1123
1963	1124
1964	1125
1965	1126
1966	1127
1967	1128
1968	1129
1969	1130
1970	1131
1971	1132
1972	1133
1973	1134
1974	
1975	
1976	1135
1977	
1978	1136
1979	
1980	1137
1981	
1982	1138
1983	
1984	
1985	1139
1986	
1987	1140
1988	
1989	1141
1990	
1991	1142
1992	
1993	
1994	
1995	1143
1996	
1997	1144
1998	
1999	1145
2000	
2001	
2002	
2003	
2004	
2005	
2006	

	6.8 The use of technology
	6.8.1 Patient databases
	6.8.2 Drug information software's
7	Organisations and systems
	7.1 Role of the Ministry of Health and other organisations
	7.2 Regulation for pharmacy practice
	7.2.1 The need for regulations
	7.2.2 Licence and licensing
	7.2.3 Punishment
	7.2.4 Lack of enforcement of regulation
	7.3 Insurance
	7.3.1 The system
	7.3.2 The affect of insurance on supply of medication
	7.4 Variation between healthcare services
	7.5 Pharmaceutical industry
	7.6 Multiple health care providers
8	Physician
	8.1 Misdiagnosis
	8.2 Physician prescribing behaviour
	8.3 Prescribing error
	8.4 Handwriting
	8.5 Perception of patient that prescription prescribed by patients are safe

Appendix C

Selected quotes from the focus groups, illustrating examples of the themes that emerged

Identified themes	Human factor category	Subthemes	Quotes
1. Commercialism and commercial pressure on community pharmacies in Saudi Arabia	External factors	Healthcare system role in commercialism	<p>"I mean the proportion of safety increased because the medical insurance makes everyone go to the doctor before they go to the pharmacist, and do not take the treatment directly from the pharmacy."(I-4)</p> <p>"Listen, the biggest problem of the medical insurance is that the doctors prescribe medicines they want to sell or will gain benefit from. The most important purpose of most pharmaceutical companies, not all, nowadays, is the sales nothing else, therefore they influence some doctors to prescribe their medicines regardless the patient needs it or not... Ok. This is the main problem of the insurance, because the patient does not pay high amount, therefore the prescription contains medicines that are over the patient's need, prescribed just to be sold, no more" (I-3)</p>
	Organisational and management factors	The role of Pharmacy owners and managers	"Problems between you and the owner arise; he [the owner] asks what happened ... [you] pay a penalty, close the pharmacy and your license is suspended. These problems face us and affect our work." (CPG-4)
	Work environment	Type of pharmacy and its effect on medication safety	<p>"We talk about the chain of pharmacy we spend a lot of time to train our pharmacists before going to be behind the counter to dispense medication...Chain of pharmacy or chain group it is easy to implement any regulations"(PG-2)</p> <p>"Street pharmacies [independent pharmacies] have more problems because the responsibility is like a burden on the pharmacist's shoulders. He becomes a physician. On the other hand, when I am in a place [where] there is a clinic, half of my time is spent on prescriptions from the clinic, and the physician upstairs is doing his duty, writing the medicine that suits the patient and explaining to him the safety of the medicine. The clinic helps me, but when I work in a street pharmacy, I almost work alone, so I have to exert extra effort to explain to patients."(I-4)</p> <p>"...If you will find small pharmacies you will find most of the medication they survive on availability [availability of medication] in chain pharmacies they survive on the biggest bonuses they get." (PG-4)</p>
		Pharmacist working hours	<p>"Often, pharmacists find themselves compelled to work in place of their colleagues for extra hours. For example, the average working hours are 15 or 17 hours [a day]. Seventeen hours is a [long time]. The maximum hours we have are 15 hours for certain periods in a month." (CPG-1)</p> <p>"I don't expect someone who is frustrated can produce...there should be controls regulating the rights and obligations of the pharmacist. I know someone working for the company (name). He tells me about what is happening he is responsible of choosing the best place to open a pharmacy and he schedules the pharmacist working schedule he says our profits are millions, do not blame the pharmacist they are frustrated."(MPG-5)</p>

2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124

		Low salaries	<i>"I don't expect anything from the pharmacist, because all pharmacists are frustrated and this is due to their low salaries and the nature of their work. In a pharmacy, I noticed a pharmacist working in the middle of a hot day on Friday and he used to walk three or four kilometres."</i> (MPG-5)
	Team factors	Physician prescribing behavior	<i>"The medication is prescribed due to a commission, and this has resulted in a loss of confidence between us and physicians."</i> (MPG-7) <i>"Listen, the biggest problem of the medical insurance is that the Doctors prescribe medicines they want to sell or will gain benefit from. The most important purpose of most pharmaceutical companies, not all, nowadays, is the sales nothing else, therefore they influence some doctors to prescribe their medicines regardless the patient needs it or not. Ok."</i> (I-3)
	Task factors	Patient counselling	<i>"The pharmacists' required trait is honesty. He should be honest when giving an opinion or at least not give advice if his advice is for commercial purposes. His positive role is absent here."</i> (MPG-3) <i>"My problem is always that when I go, they give me the best and the latest on the market, that is to say, they do not give me the one appropriate for me. The problem is that they do not try to learn whether it is appropriate or not."</i> (FPG-1)
		Generic substitution	<i>"He sometimes tells you about an alternative if one drug is expensive. I hear him saying, 'its price is seventy, but there is an alternative that is only forty'."</i> (FPG-2) <i>"Price is not the issue, [it is to] prevent you [the patient] from going to other pharmacy"</i> (FPG-5) <i>"When I talk to him and he gives me options, [I think] I came to ask you! Why do you give me options? What do you like?[He asks] Do you want this medicine or is it ok with you if I give you this or this? No, I want [him] to show me"</i> (FPG-1)
2. Illegal supply of prescription medication by pharmacist	External factors		<i>"But in the past, we had same discussion by the way it is not logic that xxx dose not sell the medication without medications [means prescriptions] while my neighbour is selling without I will be broken and close my business. So, implementing in this time is very important as a chain of pharmacy owner and heading this kind of committee I think very willing we need some kind of cooperation from the Ministry of Health to encourage such way. Of course, I believe always about penalties you need to implement something you need to do it the penalties if there is a punishment for one pharmacy dispensing that everybody will commit with that."</i> (PG-2)
	Individual factors: Pharmacist		<i>"We are pharmacists, we have certificates and we know what to dispense, but there are laws controlling us."</i> (CPG-3) <i>"When you have a patient in front of you needing to be treated, it would be difficult, especially if the patient is poor and needs assistance, not to help him."</i> (CPG-4) <i>" We are not only pharmacists, but also marketers. ... I know why he wants the Liponex, whether he wants to sell or take four or five tablets ... The same happens with the psychological medication ... we may dispense it...Solving the problem of insomnia may not be that he cannot sleep, it may be depression, so we give him antidepressants like Liponex. A week prior to marriage anti-depressants may be needed, and we give Sirolex either for a man or a woman."</i> (CPG-3) <i>"The CPs should not give medications without prescription ... because they are risky."</i> (FPG-8)

2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183

3. Lack of enforcement of regulations	External factors	Regulations and regulators	<p><i>"We have three governing bodies in controlling the whole process [medication supply]: one controlling the medication SFDA, one controlling community pharmacy which is MOH, and one controlling the licensing pharmacist, I think either we have one governing body who is controlling the whole process and all effective collaborative efforts between these different agencies."</i>(PG-1)</p> <p><i>"I disagree with (PG-1) about what he mentioned about that community pharmacy practice should be under one umbrella. I think this is different because even in Europe the authority who is licensing for the pharmacist is different from the authority licensing for the pharmacy."</i>(PG-2)</p> <p><i>"The most important thing is the Ministry of Health, and it is important to inspect on the licenses of pharmacists. Does the pharmacist have a license or not? Does he have a card of the health certificate? There should be a follow-up on medicines in pharmacies. There are medicines sold which are trafficked. This would have to be controlled."</i>(I-3)</p>
	Individual factors: Pharmacist	Pharmacist adherence to law and regulations	<p><i>"No professional pharmacist will like to break the law..."</i>(PG-4)</p> <p><i>"... When someone comes requesting a combination, I make [prepare the medication as a compound] and hide it as if I am committing a crime."</i>(CPG-4)</p> <p><i>"... There is the regulation but they are playing with regulations..."</i>(PG-8)</p> <p><i>"Community pharmacy should have a sign state that no prescribed medication should be prescribed without a prescription from a physician we do have it in Arabic written everybody can read, ok. The problem community pharmacy pharmacists although there is a sign they are still selling medications without prescription."</i>(PG-1)</p> <p><i>"There is no enforcement on pharmacists for example to label products although the law is saying you have to label products the law is saying you have to dispense with prescription ... [moving his head] they are not doing. The only control that I can say fairly is the narcotic controlled medication."</i>(PG-4)</p>
	Medication factors	Counterfeit medication as consequence	<p><i>"I have encountered a lot of counterfeit products It is not medicines but other things, for example, herbs. Many medicines are from natural herbal components, but their origins or their producers are not known, and even there is nothing written on it, and not licensed by the Saudi Ministry of Health."</i>(I-3)</p> <p><i>"in Saudi Arabia counterfeit is not a major problem because the system we are going through and the good control of the port in general"</i>(PG-4)</p> <p><i>"I think the worst that we suffer regarding medications is fraud ... they could be counterfeit"</i>(FPG-9)</p>
4. Healthcare system in KSA	External factors	The fragmented healthcare system	<p><i>"...And I remember one time one patient like he has two different insurance he went to two different doctors and get the same medication from the different insurance ... so we also we need to connect all three [pharmacy, patient, health insurance system] together so we have a system for the insurance for this patient if he has two insurance so he will not abuse this insurance by getting the same kind of medication from different pharmacy or different hospitals."</i>(PG-5)</p>
		Lack of patient database in community pharmacies	<p><i>"when PG-6 mentioned about the filing lets go even to institutions in the government you find some patients going to different hospitals with no common filing this is a problem starting from the beginning not from the community which is in the end of the road this is one of the problems I know some people going to different hospitals to get the same medication this is I think a problem. However, I am just wondering about it. This the time I think the MOH to upgrade the behaviour [to implement a filling system]."</i>(PG-2)</p> <p><i>"He dispenses medication based on what information you provide him; nothing [is] documented"</i>(MPG-7)</p>

2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242

	Organizational and management factors	Implementation of technology in community pharmacy	<i>"In America, there is a program contains the name of the medication to be dispensed drug-drug interaction. This system is good and increases the safety of medications and as to the problem of expiration"</i>
5. Patient medication taking behavior		Self-medication	<p>CPG-2: <i>I add the point of the medication, which needs monitoring at intervals such as vitamin D3 and it is of no use being taken randomly without measuring the levels at start. I see them may take the Swiss vitamin D3 (big clap) Each week he takes one bottle just because he thinks he is suffering from osteoporosis</i></p> <p>CPG-4: <i>and this is what is common nowadays</i></p> <p>CPG-1: <i>what is common nowadays is that they suffer from vitamin D deficiency and then take it without taking baseline levels."</i></p> <p><i>"As for the medicine with severe risk that contains cortisone, most women especially here in the KSAuse cortisone [Steroids] for weight gain, [...] Unfortunately, they take it a lot and repeatedly. They may take it monthly for many times."</i>(I- 3)</p> <p><i>"Yes, it is the core problem [self-medication]" (MPG-5)</i></p> <p><i>"Regrettably, the issue is the culture of the society, the easiness of obtaining some medications. No need to go far, in the United Arab Emirates, the antibiotic is taken through a prescription whereas in our country, you can take any kind of medications even it is controlled and even from private clinics."</i>(MPG-6)</p>
		Sharing medication	<p>CPG-1: Cooperation, that is, I have a pharmacy at home</p> <p>CPG-5: as fruits in the refrigerator.</p> <p>Moderator: Well, does that mean all your medications are shared?</p> <p>CPG-1: No, not to this extent, may be antibiotic without exaggeration.</p> <p>Moderator: Could give me examples?</p> <p>CPG-5: When I travel abroad I always have a packet of zithromyx and of course Fevadol, sprays and all medications that I will face a problem their not getting them.</p> <p>Moderator: do you share medications with the family, participant 4-3 and participant CPG-4?</p> <p>CPG-4: Personally, I am careful with regard to medications, particularly antibiotics and I am careful not to be taken by my children unless for a compelling reason or according to specific instructions. That is, cautiousness with medications, specially, antibiotics. As to sharing, I don't share may be Panadol or painkiller.</p>
		Adherence to medication	<i>"Yesterday, I was chatting with one of my friends. He said: while we were moving from house to house, we found a drawer in my mother's room, when we open it; we found it full of medications. She used to bring medication from the hospital and place there so as not to use it. She admits only hypertension and cholesterol; in case of any other medical problems she hides its medication from her sons and daughters."</i> (MPG-6)

2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295
2296
2297
2298
2299
2300
2301

<p>6. Patient trust in pharmacists</p>			<p><i>"If working in the government sector, I think they could be honest as most of them are Saudis, with Saudi certificates, the foreigners you cannot know if they have qualification in the field or only salesmen [...] certain places offer fraud certificates, but I do not know more details."</i>(FPG-1)</p> <p><i>"We have many cases ... they do not know anything, sometimes they do not even know BID [to be taken two times a day]."</i> (PG-2)</p> <p><i>"Many thanks for him now because he refused to give medicine that was inappropriate ... the pharmacist was honest; he seemed to be newly appointed."</i>(FPG-3)</p> <p><i>"Patients trust their doctor even if he made a mistake in something; patients never trust anybody else because they fully rely on the doctor."</i>(I-3)</p> <p><i>"I see if there is commitment and standards from the pharmacist. [This is] part sincerity. He asks you some questions to make you feel that he is careful, not just give and take some time, they just can get a member of staff to do that."</i>(MPG-2)</p>
<p>7. Communication and information exchange</p>		<p>Patient-pharmacist communication</p>	<p><i>"The pharmacist should care about communication with the patient and not get bored questioning the patient. Despite the feeling that the patient does not want to be asked a lot of questions, the pharmacist should do what is best for him ethically. The goal is the patient's benefit."</i>(CPG-1)</p> <p><i>"My work depends on communication with my patients."</i>(CPG-4)</p> <p><i>"I did not ask, but he was proactive. Just a little information about the medication and I will be thankful, as he is the specialist. I am sure that some of the medications have red lines [cautions]. Even if they are licensed, I need to be informed about the cautions on them."</i>(MPG-2)</p> <p><i>"I think education (being proactive) is not the role of the pharmacist. It is impossible to explain everything to everyone. If the patient asks, he should answer; if the patient does not ask, it is not the role of the pharmacist to explain."</i>(MPG-4)</p>
		<p>Patient medication information source</p>	<p><i>"I read a package insert with a lot of information warnings and side effects, I always get afraid ... I immediately get my eye glasses and start reading... So even the words they use are harmful, especially when they say 1 in 100,000, some words hurt."</i> (MPG-4)</p>
		<p>Factors affecting communication exchange</p>	<p><i>"The pharmacists they are male pharmacists, so the females most of them are sending their driver to get their medication they may not ask questions that can be a communication barrier. Many families send the driver to get the medication"</i> (PG-3)</p> <p><i>"He gave him many options, maybe his child's age, I don't know, but he gave him options and explained [things] to him and gave him more time. I kept waiting. When it was my turn, he said to me, 'this is the best, so take it.'"</i>(FPG-1)</p> <p><i>"...There is no chair in the reception, in the middle in front of him, a large space so he can put Strepsils and gum. You go abroad; there are chairs for waiting because he knows he will take some of my time to discuss information with the patient before me ... no chairs for waiting, and if you wait, don't expect them to tell you anything."</i>(MPG-5)</p>

2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360

		Type of information requested by patients from pharmacists	<p>Moderator: <i>what are the most questions that you may ask?</i></p> <p>MPG-2: <i>the most important matter is to ask him about its side effects</i></p> <p>MPG-1: <i>Correctly</i></p> <p>MPG-2: <i>what does the medication do? What is it composed of? Should I continue? Should I continue the dose? May I reduce it? Is it taken when necessary?</i></p> <p>MPG-7: <i>the important matter that I ask the pharmacist about is: for what problem is this medication taken for? That is in order to know whether the problem is actually a disease or not"</i></p>
		Information received from pharmacist information compared to information received from physician	<p><i>"The physician says, 'Because of so and so this is no longer of benefit', and when you go to the pharmacist, he gives another opinion. There is always a struggle inside of us about who to believe." (MPG-1)</i></p> <p><i>"This is not the role of the pharmacist. If I take two prescriptions, it is not his role to tell me ... to take this medication with that medication. It is not the responsibility of the pharmacist, not all pharmacists know drug interactions."(MPG-4)</i></p> <p>The opposite opinion was also expressed: <i>"Why did they study for five years?"(MPG-5)</i></p>
	Team factors	Communication between pharmacists and physicians	<p><i>"We also do not know how to communicate with physicians, secondly in order to communicate with him again we have to request his phone number. If I work at a pharmacy, which is far away from the clinic and try calling him my call is divert to an answer machine and they leave on hold the physician does not reply and you start from scratch to call again and stay on hold, you are keen to give the patient the right medication [...] I think there is a safety problem with the prescription trying to communicate with him would be impossible."(CPG-1)</i></p>

1148 PG Professional Group
1149 FPG Female Pharmacy Users Group
1150 CPG Community Pharmacy Group
1151 MPG Male Pharmacy Users Group
1152 I Interview participant

1153